BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33887579)

  • 1. CD45RA
    Tomita Y; Ishida H; Uehara S; Takiguchi S; Sato T; Nakamura M
    Int Immunopharmacol; 2021 Aug; 97():107661. PubMed ID: 33887579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
    Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced CD4
    Mirzakhani M; Shahbazi M; Akbari R; Oliaei F; Asgharpour M; Nikoueinejad H; Mohammadnia-Afrouzi M
    Transpl Immunol; 2020 Jun; 60():101290. PubMed ID: 32240775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
    Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
    Front Immunol; 2021; 12():716559. PubMed ID: 34335631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
    Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
    Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of CD4
    McRae JL; Chia JS; Pommey SA; Dwyer KM
    Nephrology (Carlton); 2017 Jul; 22(7):505-512. PubMed ID: 27517975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
    Kang ZY; Ma S; Liu W; Liu C
    Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
    Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
    Yanyiam P; Kantachuvesiri S; Thammanichanond D
    Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
    Wiebe C; Gibson IW; Blydt-Hansen TD; Pochinco D; Birk PE; Ho J; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2015 Nov; 15(11):2921-30. PubMed ID: 26096305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
    Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients.
    Hirai T; Furusawa M; Omoto K; Ishida H; Tanabe K
    Transplantation; 2014 Aug; 98(4):443-50. PubMed ID: 24717219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies.
    Subburayalu J; Dolff S; Xu S; Sun M; Lindemann M; Heinold A; Heinemann FM; Tervaert JWC; Eisenberger U; Korth J; Brinkhoff A; Kribben A; Witzke O; Wilde B
    Clin Immunol; 2021 May; 226():108698. PubMed ID: 33639275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis patients have reduced resting and increased activated CD4
    Verma ND; Lam AD; Chiu C; Tran GT; Hall BM; Hodgkinson SJ
    Sci Rep; 2021 May; 11(1):10476. PubMed ID: 34006899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different phenotypes of CD4
    Wang K; Song ZL; Wu B; Zhou CL; Liu W; Gao W
    Int Immunopharmacol; 2019 Apr; 69():194-201. PubMed ID: 30735938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.
    Gramkow AM; Baatrup JH; Gramkow ET; Thiesson HC; Koefoed-Nielsen P
    Pediatr Transplant; 2024 Aug; 28(5):e14773. PubMed ID: 38808702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.